Patrick Amstutz
Vermögen: 3 Mio $ am 30.06.2026
Vermögen: 3 Mio $ am 30.06.2026
Patrick Amstutz is the founder of Molecular Partners AG, founded in 2004, holding the title of Chief Executive Officer & Director since 2017.
Dr. Amstutz currently holds the positions of Chief Executive Officer & Director at Molecular Partners, Inc. and President at the Swiss Biotech Association since 2022.
Dr. Amstutz completed a doctorate at the University of Zurich and a graduate degree at the Swiss Federal Institute of Technology.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MOLECULAR PARTNERS AG 1,88 % | 31.12.2025 | 759 913 ( 1,88 % ) | 3 Mio $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MOLECULAR PARTNERS AG | Gründer | 22.11.2004 |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | Präsident | 03.05.2022 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Vorstandsvorsitzender | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
University of Zurich
University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Partners AG
Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | Commercial Services |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen